Finanical Reports

Explore the landscape of Finanical Reports in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Finanical Reports to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer
CompanyDrug

Hengrui Wins NMPA Trial Clearance for First-in-Class SHR-2005 Combination in Bladder Cancer

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that China's National Medical Products Administration (NMPA) has approved the initiation of a clinical trial of SHR‑2005 injection, in combination…

AstraZeneca's Imfinzi Combo Cuts Death Risk 42% in Phase III VOLGA Trial – Landmark Perioperative Win in Muscle-Invasive Bladder Cancer

AstraZeneca’s Imfinzi Combo Cuts Death Risk 42% in Phase III VOLGA Trial – Landmark Perioperative Win in Muscle-Invasive Bladder Cancer

InnoCare Pharma Q3 Revenue Surges 150.6% as Orelabrutinib Expansion Drives Turnaround to Profitability

InnoCare Pharma Q3 Revenue Surges 150.6% as Orelabrutinib Expansion Drives Turnaround to Profitability

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

Huadong Medicine Reports 10.4% Revenue Growth in Q3 2022

Company

Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline

Company

Abbott Reports Q3 Sales Growth, Raises Full-Year EPS Guidance

Company

Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance

Company

Zai Lab Reports Strong Revenue Growth in 2022 Interim Results

Company

Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results

Company

Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges

Company

SciClone Pharmaceuticals Reports 10.8% Revenue Growth in 2022 Interim Results

Show More